181 related articles for article (PubMed ID: 37353376)
41. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.
Resch I; Bruchbacher A; Franke J; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
ESMO Open; 2021 Aug; 6(4):100122. PubMed ID: 34217917
[TBL] [Abstract][Full Text] [Related]
42. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
43. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
44. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
[No Abstract] [Full Text] [Related]
45. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
46. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
48. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.
Johnston H; Deal AM; Morgan KP; Patel B; Milowsky MI; Rose TL
Clin Genitourin Cancer; 2023 Jun; 21(3):357-365. PubMed ID: 37012148
[TBL] [Abstract][Full Text] [Related]
49. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
50. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
51. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Soares A; Monteiro FSM; da Trindade KM; Silva AGE; Cardoso APG; Sasse AD; Fay AP; Carneiro APCD; Alencar Junior AM; de Andrade Mota AC; Santucci B; da Motta Girardi D; Herchenhorn D; Araújo DV; Jardim DL; Bastos DA; Rosa DR; Schutz FA; Kater FR; da Silva Marinho F; Maluf FC; de Oliveira FNG; Vidigal F; Morbeck IAP; Rinck Júnior JA; Costa LAGA; Maia MCDF; Zereu M; Freitas MRP; Dias MSF; Tariki MS; Muniz P; Beato PMM; Lages PSM; Velho PI; de Carvalho RS; Mariano RC; de Araújo Cavallero SR; Oliveira TM; Souza VC; Smaletz O; de Cássio Zequi S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):183. PubMed ID: 38594593
[TBL] [Abstract][Full Text] [Related]
52. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
53. A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma.
Song Y; Du C; Zhang W; Sun Y; Yang L; Cui C; Chi Y; Shou J; Zhou A; Wang J; Sun Y
Asia Pac J Clin Oncol; 2016 Jun; 12(2):174-80. PubMed ID: 26997520
[TBL] [Abstract][Full Text] [Related]
54. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
55. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
56. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
Calvo E; Grünwald V; Bellmunt J
Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
[TBL] [Abstract][Full Text] [Related]
57. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
58. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
59. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
[No Abstract] [Full Text] [Related]
60. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Navani V; Ernst MS; Wells JC; Meza L; Pal SK; Lee JL; Li H; Agarwal N; Alva AS; Hansen AR; Basappa NS; Szabados B; Powles T; Tran B; Hocking CM; Beuselinck B; Yuasa T; Choueiri TK; Heng DYC
J Urol; 2023 Apr; 209(4):701-709. PubMed ID: 36573926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
